TRIDESILON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIDESILON (TRIDESILON).
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
| Metabolism | Desonide is metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. Topical application results in minimal systemic absorption, but extensive use on large areas or under occlusion can lead to sufficient systemic absorption for hepatic metabolism. |
| Excretion | Primarily hepatic metabolism; metabolites excreted renally (70%) and in feces (30%). |
| Half-life | 2–3 hours (topical); 1–2 hours (systemic) after IV, with clinical duration prolonged due to tissue binding. |
| Protein binding | 85–90%, primarily to albumin, less to alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.0–1.5 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Topical: minimal systemic absorption (∼1–5%); oral: not available; IM: 100%. |
| Onset of Action | Topical: 30 minutes – 1 hour; Intramuscular: 1–2 hours; Intravenous: rapid (minutes). |
| Duration of Action | Topical: 3–6 hours; Intramuscular: 6–12 hours; immediate-release IV: 2–3 hours. |
0.05% ointment or cream applied topically to affected area twice daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No adjustment necessary for topical use; systemic absorption is minimal. |
| Liver impairment | No adjustment necessary for topical use; systemic absorption is minimal. |
| Pediatric use | Use smallest amount effective; apply sparingly to affected area once or twice daily, not exceeding 2 weeks of continuous use. |
| Geriatric use | Use with caution due to thinner skin; apply sparingly to affected area once or twice daily for shortest duration necessary. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRIDESILON (TRIDESILON).
| Breastfeeding | Systemic corticosteroids are excreted in breast milk, but desonide is a low-potency topical agent with minimal systemic absorption. M/P ratio is unknown. Use with caution; avoid application to breast area and limit duration/area to reduce infant exposure. In general, topical corticosteroids are considered compatible with breastfeeding. |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for major malformations when used in pregnancy, but systemic absorption can occur with extensive use. For Tridesilon (desonide), a low-potency corticosteroid, the risk is minimal. First trimester: No well-controlled studies; animal data suggest low risk. Second/Third trimester: Avoid prolonged use or large areas; may cause fetal growth restriction or adrenal suppression if significant systemic absorption. Overall, FDA Pregnancy Category C. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to desonide or any component of the formulation.","Untreated fungal, bacterial, or viral infections in the application area.","Ophthalmic use due to risk of glaucoma and cataracts."]
| Precautions | ["Topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use or use on large body surface areas.","Local adverse reactions include skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, and perioral dermatitis.","Systemic effects such as Cushing's syndrome, hyperglycemia, and glucosuria can occur with extensive use.","Not for ophthalmic use; contact dermatitis may occur."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of systemic absorption (adrenal suppression, Cushing's syndrome) if used extensively. For prolonged use or large areas, consider fetal growth surveillance. No specific fetal monitoring required for low-potency topical use. |
| Fertility Effects | No known adverse effects on fertility. Animal studies have not shown impairment. Human data are lacking. |